Annaert P, Van Gelder J, Naesens L, De Clercq E, Van den Mooter G, Kinget R, Augustijns P
Laboratorium voor Farmacotechnologie en Biofarmacie, KULeuven, Belgium.
Pharm Res. 1998 Aug;15(8):1168-73. doi: 10.1023/a:1011923420719.
To investigate the role of carrier mechanisms in: [1] the polarized transport of the bis(pivaloyloxymethyl)- [bis(POM)-] ester prodrug of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine [PMEA] and [2] the directional secretion of its metabolites.
Caco-2 monolayers were used to study the modulation effect of carriers on the transport of bis(POM)-PMEA and the efflux of intracellularly formed metabolites mono(POM)-PMEA and PMEA from the cells. The interaction of bis(POM)-PMEA and its metabolites with the efflux mechanisms present in Caco-2 monolayers was investigated by testing the effect of various concentrations of verapamil (30, 100, 300, microns) or indomethacin (10-500 microns) on transport and efflux.
Polarity in transport of bis(POM)-PMEA (50 micron) across Caco-2 monolayers was noted: transport of total PMEA [=bis(POM)-PMEA, mono(POM)-PMEA and PMEA] was significantly higher in basolateral (BL) to apical (AP) direction (14.5 +/- 0.4%) than transport in the opposite (AP to BL) direction (1.7 +/- 0.2%). This difference was reduced in a concentration dependent way when verapamil (0-100 microns) was included in both AP and BL incubation media. After loading the cells with bis(POM)-PMEA (100 micron) for 1 hr, studies on efflux of PMEA and mono(POM)-PMEA from the Caco-2 monolayers over a 3 hr period, revealed that both metabolites were preferentially secreted towards the AP compartment. Efflux of PMEA toward AP and BL compartments amounted to 14.6 +/- 1.1% and 5.3 +/- 0.4, respectively, of the initial intracellular amount of total PMEA, while efflux of mono(POM)-PMEA towards AP and BL compartments was limited to 2.3 +/- 0.1% and 0.5 +/- 0.1%, respectively. When 10 micron indomethacin was included in the AP incubation medium, efflux of PMEA was decreased to 7.8 +/- 0.3% and 3.3 +/- 0.3% towards the AP and BL compartments, respectively. The decrease in efflux by indomethacin was concentration-dependent up to 100 micron. Transepithelial transport of total PMEA was also reduced in the presence of 30 micron indomethacin, as reflected in smaller concentrations of PMEA and mono(POM)-PMEA in the acceptor compartment, irrespective of the transport direction.
The data obtained in this study suggest that bis(POM)-PMEA is substrate for a P -glycoprotein-like carrier mechanism in Caco-2 monolayers, while its metabolites mono(POM)-PMEA and PMEA are transported by a non-P-glycoprotein efflux protein.
研究载体机制在以下方面的作用:[1]抗病毒药物9-(2-膦酰甲氧基乙基)腺嘌呤[PMEA]的双(新戊酰氧甲基)-[双(POM)-]酯前药的极化转运,以及[2]其代谢产物的定向分泌。
使用Caco-2单层细胞研究载体对双(POM)-PMEA转运以及细胞内形成的代谢产物单(POM)-PMEA和PMEA从细胞中流出的调节作用。通过测试不同浓度的维拉帕米(30、100、300微摩尔)或吲哚美辛(10 - 500微摩尔)对转运和流出的影响,研究双(POM)-PMEA及其代谢产物与Caco-2单层细胞中存在的流出机制的相互作用。
观察到双(POM)-PMEA(50微摩尔)跨Caco-2单层细胞转运的极性:总PMEA[=双(POM)-PMEA、单(POM)-PMEA和PMEA]从基底外侧(BL)到顶端(AP)方向的转运(14.5±0.4%)显著高于相反方向(AP到BL)的转运(1.7±0.2%)。当在AP和BL孵育培养基中都加入维拉帕米(0 - 100微摩尔)时,这种差异以浓度依赖的方式减小。用双(POM)-PMEA(100微摩尔)加载细胞1小时后,对Caco-2单层细胞在3小时内PMEA和单(POM)-PMEA流出的研究表明,两种代谢产物都优先分泌到AP隔室。PMEA向AP和BL隔室的流出量分别相当于初始细胞内总PMEA量的14.6±1.1%和5.3±0.4%,而单(POM)-PMEA向AP和BL隔室的流出量分别限于2.3±0.1%和0.5±0.1%。当在AP孵育培养基中加入10微摩尔吲哚美辛时,PMEA向AP和BL隔室的流出量分别降至7.8±0.3%和3.3±0.3%。吲哚美辛引起的流出减少在浓度高达100微摩尔时是浓度依赖的。在存在30微摩尔吲哚美辛的情况下,总PMEA的跨上皮转运也减少,这反映在受体隔室中PMEA和单(POM)-PMEA的浓度较低,与转运方向无关。
本研究获得的数据表明,双(POM)-PMEA是Caco-2单层细胞中一种P-糖蛋白样载体机制的底物,而其代谢产物单(POM)-PMEA和PMEA由一种非P-糖蛋白流出蛋白转运。